Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Damora Therapeutics, Inc.NASDAQ: DMRA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's LTM Mar 2026 revenue of $0 is the 7th highest of the 9 companies compared; the peer median is $114.65M.
DMRA Competitors Peer median
Revenue for DMRA and competitors
Company Period LTM YoY 3-year CAGR
INCYIncyte CorporationLTM Jun 2026$5.82B +26.9%+14.8%
GMABGenmab A/SLTM Jun 2026$4.13B —-36.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$299.77M +47.6%+34.8%
GERNGeron CorporationLTM Mar 2026$196.12M +68.6%+575.7%
KROSKeros Therapeutics, Inc.LTM Mar 2026$33.18M -84.5%—
QUREuniQure N.V.LTM Mar 2026$18.09M -10.4%-46.7%
DMRADamora Therapeutics, Inc.LTM Mar 2026$0 ——
IRONDisc Medicine, Inc.LTM Sep 2026$0 ——
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$0 ——
Peer median (excluding DMRA) $114.65M+26.9%+14.8%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue441K490K830K181K0
Gross Profit(441K)(490K)(830K)(181K)0
Gross Margin—————
Research & Development38.49M48.21M23.77M6.4M201.19M
Selling, General & Admin13.3M12.51M11.86M10.32M9.69M
Operating Expenses51.79M60.72M35.63M16.72M210.87M
Depreciation & Amortization441K490K830K181K34K
EBITDA(51.31M)(61.13M)(37.52M)(21.22M)(209.76M)
EBITDA Margin—————
Operating Income(52.23M)(61.21M)(36.46M)(16.9M)(210.87M)
Operating Margin—————
Interest Income156K722K1.69M844K1.17M
Interest Expense00000
Other Income / Expenses475K(417K)(1.89M)(4.5M)1.08M
Income Before Tax(51.75M)(61.62M)(38.35M)(21.4M)(209.79M)
Pre-Tax Margin—————
Income Tax Expense00041K50K
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Net Margin—————
EPS (Basic)(51.22)(60.63)(36.08)(18.53)(158.13)
EPS (Diluted)(51.22)(60.63)(36.08)(18.53)(158.13)
Weighted Avg Shares1.01M1.02M1.06M1.16M1.33M
Weighted Avg Shares (Diluted)1.01M1.02M1.06M1.16M1.33M

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.